Genmab Partnering Deals and Alliances 2010 to 2017

Publisher Name :
Date: 01-Sep-2017
No. of pages: 100
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 1 working day of receipt of order. If the CD-Rom version purchased, the report will be sent by courier using express service.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of this report provide an orientation of deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&A deals since 2010 to present date based on headline value.

Chapter 4 provides details on how to approach biopharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where biopharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6 providing a infographic visual summary of the company‘s partnering activity since 2010 according to deal type, industry sector, phase of development, and therapy area.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners' negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment of the following:

o What is actually granted by the agreement to the partner company?

o What exclusivity is granted?

o What is the payment structure for the deal?

o How are sales and payments audited?

o What is the deal term?

o How are the key terms of the agreement defined?

o How are IPRs handled and owned?

o Who is responsible for commercialization?

o Who is responsible for development, supply, and manufacture?

o How is confidentiality and publication managed?

o How are disputes to be resolved?

o Under what conditions can the deal be terminated?

o What happens when there is a change of ownership?

o What sublicensing and sub-contracting provisions have been agreed?

o Which boilerplate clauses does the company insist upon?

o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

o Which jurisdiction does the company insist upon for agreement law?

Partnering Deals and Alliances since 2010 report provides the user with the following key benefits:

Partnering interests and therapy focus revealed

Partnering activity since 2010 - number of deals per year

Partnering activity for 2010-present

Activity by deal type

Activity by phase of development

Activity by therapeutic area

List of recent partner companies

Detailed listing of all partnering deals since 2010

Comprehensive access to actual contracts entered into by the company and its partners*

Insight into the terms included in a partnering agreement

Understand the key deal terms the company has agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

*Subject to being published via regulatory requirements of the Securities Exchange Commission.

Genmab Partnering Deals and Alliances 2010 to 2017

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Most active partner companies
2.1 Most frequent partner companies

Chapter 3 - Top deals by value
3.1 M&A
3.2 Partnering

Chapter 4 - Submitting Opportunities
4.1 How to submit an opportunity
4.2 Opportunity submission template
4.3 Sending emails
4.4 Face to face at partnering events
4.5 Online submission forms

Chapter 5 - Forthcoming partnering events
5.1 Forthcoming events

Chapter 6 - Partnering and M&A directory since 2010
6.1 How to use directory
6.3 Company directory
Infographic summary for partnering activity since 2010
Partnering deals directory - by company A-Z
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - M&A
Partnering deals directory - by stage of development
Partnering deals directory - by therapy area
Partnering deals directory - by technology area
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering

List of Figures

Figure 1: Most frequent partner companies since 2010
Figure 2: Leading M&A deals by value since 2010
Figure 3: Leading partnering deals by value since 2010
Figure 4: Typical partnering opportunity submission template
Figure 5: Dealmaking frequency since 2010
Figure 6: Recent deals by industry sector
Figure 7: Recent deals by deal type
Figure 8: Recent deals by stage of development
Figure 9: Recent deals by therapy area
Figure 10: Recent deals by technology area
  • United States DNA Forensic Market Report 2017
    Published: 19-Jan-2018        Price: US 3800 Onwards        Pages: 114
    In this report, the United States DNA Forensic market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of DNA......
  • Fill Finish Manufacturing Market by Product (Consumables (Vial, Prefilled Syringes (Glass, Plastic), Cartridge, Single Use Systems), Instruments), End User (Contract Manufacturing Organization, Biopharmaceutical Company, CROs) - Global Forecast to 2022
    Published: 19-Jan-2018        Price: US 5650 Onwards        Pages: 123
    “The fill-finish manufacturing market is projected to register a CAGR of 8.6%.” The fill-finish manufacturing market is expected to reach USD 4.47 billion by 2022 from USD 2.96 billion in 2017, growing at a CAGR of 8.6% during the forecast period. Technological advancements in fill-finish products, growth of the biopharmaceutical industry, rising adoption of prefilled syringes, and increase in fill-finish outsourcing are the major factors driving this mark......
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 3500 Onwards        Pages: 41
    Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2018 Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Pipe......
  • Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 3500 Onwards        Pages: 77
    Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2018 Summary Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Peroxisome proliferator-a......
  • United States Phloem Fibre Market Report 2018
    Published: 18-Jan-2018        Price: US 3800 Onwards        Pages: 101
    In this report, the United States Phloem Fibre market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Phl......
  • Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 3500 Onwards        Pages: 96
    Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2018 Summary According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H1 2018'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoi......
  • Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 3500 Onwards        Pages: 80
    Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2018 Summary Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.......
  • Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 3500 Onwards        Pages: 39
    Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H1 2018 Summary Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling i......
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 3500 Onwards        Pages: 44
    Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H1 2018 Summary Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs